Introduction
============

Malignant main stem bronchial tumors (MBTs) are a group of extremely rare neoplasms situated in large airways between the carina and hilum of the lung, which represents \<0.6% of pulmonary tumors.[@b1-ott-11-083] A number of MBTs are misdiagnosed as asthma or chronic obstructive pulmonary disease in the early stages due to negative chest X-ray findings and nonspecific symptoms caused by airway obstruction or secondary pulmonary infections.[@b2-ott-11-083],[@b3-ott-11-083] With the development of flexible bronchoscopy, there has been an increase in the diagnosis of MBTs.[@b4-ott-11-083] Surgery, radiotherapy, and chemotherapy are the main treatment strategies for MBTs;[@b2-ott-11-083],[@b5-ott-11-083],[@b6-ott-11-083] however, because of the rarity of MBTs, there is little experience targeting factors influencing prognosis based on large samples, and guidelines for the TNM staging system have not been provided. Thus, it is necessary to precisely predict prognosis when selecting a therapeutic strategy of MBTs.

Nomography, a statistic-based tool to quantify risk by incorporating and illustrating clinical factors of a tumor, has been widely used to predict survival of cancer patients.[@b7-ott-11-083]--[@b10-ott-11-083] Nomograms have been shown to have good accuracy and have even been proposed as a new standard.[@b11-ott-11-083] The advantage of nomography, including visual and quantifiable features, makes nomography user friendly for physicians and patients. Therefore, in this study, we used nomograms along with univariate and Cox hazards regression analyses to identify risk factors affecting overall survival (OS) of MBTs and develop a nomogram to predict the prognosis for MBTs patients based on the data derived from the Surveillance, Epidemiology, and End Results (SEER) database.

Patients and methods
====================

Study population
----------------

The data used in this study were retrieved from the SEER database (<http://seer.cancer.gov/>), which is freely available to the public. The SEER program of the National Cancer Institute is an authoritative source of information on cancer incidence, prevalence, mortality, population-based variables, primary tumor characteristics, and treatment, and covers approximately 28% of the US population.[@b12-ott-11-083]

SEER\*Stat software was used to examine the target population from the data between 1973 and 2014. Patients with the following criteria were included in this study: the primary tumor site was the main stem bronchus, and the follow-up survival months had complete dates, and there was \>0 day of survival. The following information was collected for each patient from the SEER database: the demographics of patients (age at diagnosis, gender, and race/ethnicity); characteristics of tumors (tumor size, involvement of lymph nodes, tumor extension, pathologic grade, and histologic type); therapy details (surgery, radiotherapy, and chemotherapy); and follow-up records (cause of death, cancer-specific death, and survival months). Patients missing the aforementioned data were excluded.

Characteristics of patients
---------------------------

For further analysis, some variables were divided into different subgroups. The histologic types of tumors were categorized into five groups, including squamous cell carcinoma (SQCC), adenocarcinoma (AC), large-cell carcinoma (LCC), small-cell carcinoma (SMCC), and others (sarcoma, adenosquamous cancer, and other types not categorized as above). Involvement of lymph nodes were divided into three grades (no involvement, involvement of local lymph nodes \[ipsilateral nodes of bronchi, hilus of the lung, pulmonary ligament, intrapulmonary nodes, aortic nodes, carinal nodes, pericardial nodes, peri-/paraesophageal nodes, and peri-/paratracheal nodes\], and involvement of distant nodes \[supraclavicular nodes, contralateral nodes of the hilus, mediastinum, and bronchopulmonary nodes\]). With respect to the level of tumor extension, distant extension includes pleural effusion, contralateral lung and main stem bronchi, pericardium, trachea, esophagus, pulmonary ligament, pulmonary artery or vein, azygos vein, aorta and vena cava, chest wall, diaphragm, or other organs beyond the thoracic cavity.

Statistical analysis
--------------------

Survival curves for each variable were evaluated using the Kaplan--Meier method and were compared using the log-rank test. Variables in which the significance of probability (*P*) value was \<0.05 were used in multivariate analysis performed using the Cox proportional hazards regression model. Statistical analyses to identify independent prognostic factors were performed using SPSS 24.0 (IBM Corp., Armonk, NY, USA) for Windows.

The cumulative incidence function (CIF) of MBT-specific deaths based on the competing risk model was used as a validation of univariate analysis.[@b13-ott-11-083] Other causes of death were competing events for MBT-specific deaths in the model. Gray test, a special test for the competing risk model, was used for evaluation, in which a *P*-value \<0.05 was considered to have statistical significance.

A nomogram on the basis of the results of multivariate analysis was formulated using the survival and rms package in R 3.4.0 (<http://www.r-project.org>). The strength of rank correlation between the predicted probability and actual responses of the nomogram was measured by calculating the concordance index (C-index). The C-index ranges from 0.5 to 1.0 and a larger C-index indicates better accuracy for predicting prognosis.[@b14-ott-11-083] The calibration plot based on bootstrap resampling validation of the nomogram was performed by comparing the predicted survival with the observed survival. In addition, competing risks analysis was performed using the function of CumIncidence. R based on the cmprsk R package.[@b15-ott-11-083]

Results
=======

The proportion of MBTs among all pulmonary tumors is approximately 4.9% (4.94K/1.04M) in the SEER database. A group of 49,368 patients with MBTs were identified; patients with missing records or exact data on any of the abovementioned examined variables were excluded. The selection process is shown in [Figure 1](#f1-ott-11-083){ref-type="fig"}. Thus, a total of 7,418 patients were included in the current study.

Survival analysis
-----------------

Of the 7,418 patients in the current study, the median follow-up time was 10 months (range, 4--22 months) and the overall 5-year survival rate was 11.9% (95% CI, 11.1%--12.7%). The OS curve is shown in [Figure 2](#f2-ott-11-083){ref-type="fig"}.

The results of univariate analysis are displayed as Kaplan--Meier curves. As shown in [Figure 3](#f3-ott-11-083){ref-type="fig"}, among the demographic data younger age (*P*\<0.001, [Figure 3A](#f3-ott-11-083){ref-type="fig"}) and female gender (*P*=0.047, [Figure 3B](#f3-ott-11-083){ref-type="fig"}) were associated with better prognosis, but there was no statistically significant difference as a function of race (*P*=0.400, [Figure 3C](#f3-ott-11-083){ref-type="fig"}).

The correlation between the characteristics of MBTs and prognosis is shown in [Figure 4](#f4-ott-11-083){ref-type="fig"}. Survival outcome differed with histologic type (*P*\<0.001, [Figure 4A](#f4-ott-11-083){ref-type="fig"}). SMCC, LCC, and AC had a similar 5-year survival rate, which was worse than SQCC and other types. Furthermore, when assessing pathologic grade, it was also shown that better differentiation was associated with more favorable survival (*P*\<0.001, [Figure 4B](#f4-ott-11-083){ref-type="fig"}). In addition, larger tumor size (*P*\<0.001, [Figure 4C](#f4-ott-11-083){ref-type="fig"}), involvement of lymph nodes (*P*\<0.001, [Figure 4D](#f4-ott-11-083){ref-type="fig"}), and distant extension (*P*\<0.001, [Figure 4E](#f4-ott-11-083){ref-type="fig"}) were also independent risk factors in prognosis of MBT.

As shown in [Figure 5](#f5-ott-11-083){ref-type="fig"}, patients who underwent surgery (*P*\<0.001, [Figure 5A](#f5-ott-11-083){ref-type="fig"}) and chemotherapy (*P*\<0.001, [Figure 5B](#f5-ott-11-083){ref-type="fig"}) had significantly better survival, while radiotherapy was not a risk factor (*P*=0.690, [Figure 5C](#f5-ott-11-083){ref-type="fig"}). Radiotherapy, however, had a different effect which depended on whether or not patients had undergone surgery. Radiotherapy had an unfavorable influence for surgery patients, but showed an association with better prognosis in patients without surgery. The details of the correlation between survival and factors mentioned above are shown in [Table 1](#t1-ott-11-083){ref-type="table"}.

The CIF of MBT-specific death based on the competing risk model are listed in [Table S1](#SD1-ott-11-083){ref-type="supplementary-material"}, and showed a consistent result compared to univariate analysis.

All significant risk factors in univariate analysis were applied to multivariate analysis. The results of Cox hazards regression analyses are listed in [Table 2](#t2-ott-11-083){ref-type="table"} and showed that age (*P*\>0.001), gender (*P*\<0.001), pathologic grade (*P*\<0.001), histologic type (*P*=0.001), surgery (*P*\<0.001), tumor size (*P*\<0.001), involvement of lymph nodes (*P*\<0.001), and tumor extension (*P*\<0.001) remained independent risk factors in the Cox model.

The nomogram, which incorporated independent significant risk factors based on the Cox model and included all 7,418 patients, is shown in [Figure 6](#f6-ott-11-083){ref-type="fig"}. It is a convenient process to predict 1-, 3-, or 5-year OS by the nomogram. We first needed to collect all information of risk factors in the nomogram of the patient, and then we assigned a score for each predictor according to the upper scale, and summed these scores to get an event probability by referring to the bottom three score scale. The nomogram had a C-index of 0.672 (95% CI, 0.664--0.680), showing good predictive ability. The calibration plots based on bootstrap resampling validation is illustrated in [Figure 7](#f7-ott-11-083){ref-type="fig"}, and showed good agreement with the reality of observation for 1-, 3-, and 5-year OS.

Discussion
==========

Primary MBTs are rare and represent approximately 4.9% of pulmonary tumors in the SEER database, which is higher than past experience. There are no reliable guidelines for treatment of MBTs; thus, designing a prognostic model is one approach to predict the outcome and develop better therapeutic strategies. With univariate and multivariate analyses of 7,418 cases, we identified a group of risk factors, including advanced age, male gender, high pathologic grade, specific histologic types, large tumor size, involvement of lymph nodes, distant extension, and untreated by surgery, radiotherapy, or chemotherapy, then developed a nomogram to predict 1-, 3-, and 5-year OS rates of patients with MBTs visually and intuitively based on these significant factors. In this way, treatment guidelines and prediction of outcomes would be more efficient and accurate for physicians and patients.

It can be seen from the nomogram that one of the most important risk factors impacting OS is age. The prognosis of young patients is far better than older patients. In the elderly, changing the chest wall structure and reduction of the diaphragm curvature reduce the efficiency of respiratory muscles.[@b16-ott-11-083] In addition, increasing the pulmonary artery and pulmonary wedge pressures and reducing the pulmonary capillary volume compromise gas exchange.[@b17-ott-11-083] Thus, a decline in pulmonary function with aging would increase the risk of respiratory failure caused by airway obstruction of MBTs in aging patients. Otherwise, many nonpulmonary conditions associated with aging, such as malnutrition, renal failure, and heart disease, would reduce treatment tolerance and worsen the prognosis for elderly patients.[@b18-ott-11-083],[@b19-ott-11-083]

Another significant factor was surgery. For those low-grade MBTs, such as SCC in the early stages, carcinoid tumors, and adenoid cystic cancer, airway resection and reconstruction is considered as a curative approach.[@b20-ott-11-083] The surgical procedures include sleeve resection, lobectomy, and pneumonectomy, while sleeve resection is widely accepted for the management of MBTs because the lung parenchyma and pulmonary preservation are preserved.[@b1-ott-11-083],[@b5-ott-11-083],[@b21-ott-11-083] If resectable, a number of low-grade MBTs have no tendency for recurrence.[@b20-ott-11-083] Like tracheal tumors, negative surgical margins and lymph node status have a significant association with survival outcomes of MBTs;[@b6-ott-11-083],[@b21-ott-11-083] however, with the development of endoscopy, those patients with nonresectable MBTs or at high surgical risk will benefit from a bronchoscopic approach. Bronchoscopic resection has shown good outcomes in a number of MBTs.[@b22-ott-11-083]--[@b24-ott-11-083] Photodynamic therapy, cryotherapy, and airway stenting are alternatives under bronchoscopy in the case of central airway obstruction.[@b25-ott-11-083]--[@b27-ott-11-083]

On the basis of univariate analysis and a competing risk model, radiotherapy was not a risk factor for OS. Current studies about the effect of radiotherapy for MBTs support the opposite view. Among traditional laser therapies, the neodymium yttrium--aluminum--garnet laser is one of the most used techniques for tumor debulking and urgent de-obstruction, and shows an improvement in OS and quality of life.[@b28-ott-11-083],[@b29-ott-11-083] In contrast, it is proposed that radiotherapy improves the risk of pulmonary function injury and pneumonia, and both local recurrence and toxicity occur late after radiotherapy in patients with central tumors.[@b30-ott-11-083]--[@b32-ott-11-083] As the result of our study, it is suggested that radiotherapy is more appropriate for nonsurgical patients, but not helpful to surgical patients. Nevertheless, MBT patients would likely benefit in some ways with new techniques of radiotherapy. Stereotactic body radiotherapy has shown excellent effects in patients with inoperative bronchial carcinoid and neuroendocrine tumors.[@b33-ott-11-083] The application of external beam radiotherapy is an alternative to reduce airway stenosis caused by MBTs.[@b34-ott-11-083] With the advent of bronchoscopy, brachytherapy has shown a promising effect as a palliative and curative treatment for endobronchial tumors.[@b35-ott-11-083],[@b36-ott-11-083] Chemotherapy also plays a role in some types of MBTs. Most of the patients who receive chemotherapy have small-cell carcinomas, and benefit most from chemotherapy.[@b37-ott-11-083] Chemotherapy has become an approach for malignant obstruction of the main bronchus with the development of intratumoral chemotherapy, which leads to a favorable reduction in massive non-small-cell lung cancer. Chemotherapy showed a positive effect based on multivariate analysis and the nomogram; however, patients with chemotherapy had a better short-term survival rate, but those who without that treatment had favorable long-term rates using the Kaplan--Meier method. It should be noted that patients treated with radiotherapy and chemotherapy were usually linked to an advanced stage and a worse physical condition. Thus, more research is needed to determine the effect of radiotherapy and chemotherapy in the treatment of MBTs.

Among characteristics of MBTs, histologic types have the most important influence on outcome because only early-stage or slow-growing MBTs are considered resectable.[@b20-ott-11-083] Tumor size also plays a significant role in predicting prognosis because a large tumor would cause worse airway obstruction and an excessive length of the involved airway is inoperable.[@b38-ott-11-083]

This study had several limitations. First, pulmonary function of MBT patients, which is believed to be an important factor for prognosis, was not evaluated. In addition, we could not obtain complete medical histories, such as smoking history or occurrence of complications. Furthermore, progression-free survival is not recorded in the SEER database, and therefore it was not taken into statistics.

Conclusion
==========

Age, gender, pathologic grade, histologic type, tumor size, involvement of lymph nodes, tumor extension, chemotherapy, and surgery were independent risk factors for OS of patients with MBTs. A nomogram was developed to predict 1-, 3-, and 5-year OS for these patients.

Supplementary material
======================

###### 

CIF of MBT-specific death based on competing risk model

  Variable             1-year CIF   3-year CIF   5-year CIF   Gray's test *P*-value
  -------------------- ------------ ------------ ------------ -----------------------
  Age (years)                                                 0.006
   0--39               34.5%±5.1%   50.8%±5.4%   58.6%±5.3%   
   40--49              45.7%±2.3%   66.9%±2.1%   70.8%±2.1%   
   50--59              45.1%±1.2%   62.2%±1.2%   65.8%±1.2%   
   60--69              45.5%±1.0%   61.6%±0.9%   64.4%±0.9%   
   70--79              45.3%±1.1%   59.3%±1.1%   61.4%±1.1%   
   80+                 47.2%±2.0%   56.9%±1.9%   58.2%±1.9%   
  Gender                                                      0.048
   Male                46.2%±0.8%   61.6%±0.7%   64.6%±0.7%   
   Female              44.3%±0.9%   60.1%±0.9%   62.3%±0.8%   
  Pathologic grade                                            \<0.001
   Grade I             34.2%±2.8%   46.6%±2.9%   49.7%±2.9%   
   Grade II            38.9%±1.1%   53.5%±1.2%   56.6%±1.1%   
   Grade III           47.4%±0.8%   62.4%±0.8%   65.0%±0.8%   
   Grade IV            50.0%±1.2%   68.0%±1.1%   70.8%±1.0%   
  Histologic type                                             \<0.001
   SCC                 41.8%±0.9%   56.8%±0.9%   60.0%±0.9%   
   AC                  46.9%±1.2%   60.3%±1.2%   63.3%±1.2%   
   LCC                 52.3%±2.5%   67.1%±2.4%   68.9%±2.3%   
   SMCC                49.4%±1.2%   69.3%±1.1%   71.8%±1.0%   
   Others              42.3%±2.5%   52.3%±2.5%   54.3%±2.5%   
  Radiotherapy                                                0.409
   No                  46.7%±1.0%   59.4%±0.9%   61.8%±0.9%   
   Yes                 44.6%±0.7%   61.8%±0.7%   64.8%±0.7%   
  Chemotherapy                                                0.030
   No                  49.5%±0.9%   59.5%±0.9%   62.0%±0.9%   
   Yes                 42.7%±0.7%   61.8%±0.7%   64.8%±0.7%   
  Surgery                                                     \<0.001
   No                  50.3%±0.6%   66.2%±0.6%   68.3%±0.6%   
   Yes                 21.5%±1.1%   35.9%±1.3%   41.7%±1.4%   
  Size (cm)                                                   \<0.001
   \<2                 27.8%±2.4%   40.7%±2.6%   44.4%±2.6%   
   2--3.9              38.5%±1.1%   53.4%±1.1%   57.4%±1.1%   
   4--5.9              46.4%±0.9%   63.0%±0.9%   65.7%±0.9%   
   6--7.9              50.6%±1.3%   66.8%±1.2%   68.5%±1.2%   
   8--9.9              54.5%±2.0%   66.8%±1.8%   68.6%±1.8%   
   ≥10                 54.6%±2.7%   69.6%±2.5%   71.5%±2.4%   
  Lymph node                                                  \<0.001
   No                  34.9%±1.1%   49.8%±1.1%   53.2%±1.1%   
   Regional LN         48.5%±0.7%   64.5%±0.7%   67.2%±0.7%   
   Distant LN          52.2%±1.9%   67.0%±1.7%   68.6%±1.7%   
  Extension of tumor                                          \<0.001
   No                  35.6%±0.8%   51.7%±0.9%   55.1%±0.9%   
   Distant extension   53.4%±0.8%   68.6%±0.7%   70.8%±0.7%   
  Race                                                        0.506
   White               45.3%±0.6%   60.9%±0.6%   63.5%±0.6%   
   Black               46.8%±1.6%   61.1%±1.6%   64.5%±1.5%   
   Others              43.2%±2.5%   61.3%±2.4%   65.3%±2.4%   

**Abbreviations:** CIF, cumulative incidence function; MBTs, malignant main stem bronchial tumors; SQCC, squamous cell carcinoma; AC, adenocarcinoma; LCC, large-cell carcinoma; SMCC, small-cell carcinoma; LN, lymph node.
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![The flow diagram of the selection process for the study.\
**Abbreviation:** MBTs, malignant main stem bronchial tumors.](ott-11-083Fig1){#f1-ott-11-083}

![Overall Kaplan--Meier survival curve of all included patients.](ott-11-083Fig2){#f2-ott-11-083}

![Overall Kaplan--Meier survival curve for patients according to (**A**) age, (**B**) gender, and (**C**) race.](ott-11-083Fig3){#f3-ott-11-083}

![Overall Kaplan--Meier survival curve for patients according to (**A**) histologic type, (**B**) pathologic grade, (**C**) tumor size, (**D**) involvement of lymph node, and (**E**) tumor extension.\
**Abbreviations:** SQCC, squamous cell carcinoma; AC, adenocarcinoma; LCC, large-cell carcinoma; SMCC, small-cell carcinoma.](ott-11-083Fig4){#f4-ott-11-083}

![Overall Kaplan--Meier survival curve for patients according to (**A**) surgery, (**B**) chemotherapy, and (**C**) radiotherapy.](ott-11-083Fig5){#f5-ott-11-083}

![A nomogram for prediction of 1-, 3-, and 5-year OS rates of patients with MBTs.\
**Abbreviations:** OS, overall survival; MBTs, malignant main stem bronchial tumors; SQCC, squamous cell carcinoma; AC, adenocarcinoma; LCC, large cell carcinoma; SMCC, small cell carcinoma;.](ott-11-083Fig6){#f6-ott-11-083}

![Calibration curve of the nomogram predicting (**A**) 1-year, (**B**) 3-year, and (**C**) 5-year OS rates of patients with MBTs.\
**Abbreviations:** OS, overall survival; MBTs, malignant main stem bronchial tumors.](ott-11-083Fig7){#f7-ott-11-083}

###### 

Patient characteristics and 1-, 3-, and 5-year OS rates

  Variable             Number of patients   Percent   1-year OS    3-year OS    5-year OS
  -------------------- -------------------- --------- ------------ ------------ ------------
  Total cases          7,418                100       40.7%±0.6%   17.0%±0.4%   11.9%±0.4%
  Age (years)                                                                   
   0--39               87                   1.2       63.1%±5.3%   43.8%±5.6%   32.0%±5.6%
   40--49              486                  6.6       48.5%±2.3%   23.0%±2.0%   16.9%±1.8%
   50--59              1,589                21.4      45.6%±1.3%   21.2%±1.1%   15.5%±1.0%
   60--69              2,578                34.8      42.8%±1.0%   18.4%±0.8%   13.0%±0.7%
   70--79              2,059                27.8      35.3%±1.1%   12.2%±0.8%   7.9%±0.6%
   80+                 619                  8.3       27.6%±1.8%   8.1%±1.2%    4.2%±0.9%
  Gender                                                                        
   Male                4,305                58.0      39.8%±0.8%   17.0%±0.6%   11.4%±0.5%
   Female              3,113                42.0      41.7%±0.9%   17.2%±0.7%   12.6%±0.6%
  Pathologic grade                                                              
   Grade I             292                  3.9       53.1%±3.0%   34.3%±2.9%   27.3%±2.8%
   Grade II            1,832                24.7      46.9%±1.2%   22.6%±1.0%   15.8%±0.9%
   Grade III           3,478                46.9      38.0%±0.8%   15.0%±0.6%   10.4%±0.6%
   Grade IV            1,816                24.5      37.5%±1.1%   12.7%±0.8%   8.6%±0.7%
  Histologic type                                                               
   SQCC                3,168                42.7      44.3%±0.9%   20.7%±0.7%   14.5%±0.7%
   AC                  1,676                22.6      37.2%±1.2%   14.9%±0.9%   9.4%±0.8%
   LCC                 386                  5.2       32.1%±2.4%   12.1%±1.7%   8.9%±1.5%
   SMCC                1,796                24.2      39.1%±1.2%   11.8%±0.8%   8.1%±0.7%
   Others              392                  5.3       41.7%±2.5%   26.5%±2.3%   21.8%±2.2%
  Radiotherapy                                                                  
   No                  2,672                36.0      38.5%±1.0%   19.0%±0.8%   14.1%±0.7%
   Yes                 4,756                64.0      41.9%±0.7%   15.9%±0.6%   10.7%±0.5%
  RT without surgery                                                            
   No RT               4,202                56.6      24.6%±1.0%   5.1%±0.5%    3.1%±0.4%
   Underwent RT        1,934                26.1      39.1%±0.8%   13.2%±0.6%   8.3%±0.5%
  RT with surgery                                                               
   No RT               738                  9.9       74.1%±1.6%   53.3%±1.9%   40.5%±1.9%
   Underwent RT        544                  7.3       62.5%±2.1%   36.2%±2.1%   28.1%±2.0%
  Chemotherapy                                                                  
   No                  2,879                38.8      33.2%±0.9%   16.9%±0.7%   12.1%±0.6%
   Yes                 4,539                61.2      45.4%±0.8%   17.1%±0.6%   11.7%±0.5%
  Surgery                                                                       
   No                  6,136                82.7      34.6%±0.6%   10.7%±0.4%   6.7%±0.4%
   Yes                 1,403                17.3      69.2%±1.3%   46.0%±1.4%   35.2%±1.4%
  Size (cm)                                                                     
   \<2                 349                  4.7       55.5%±2.7%   32.7%±2.6%   24.0%±2.5%
   2--3.9              1,874                25.3      48.8%±1.2%   24.2%±1.0%   17.5%±0.9%
   4--5.9              2,695                36.3      40.5%±1.0%   15.5%±0.7%   10.4%±0.6%
   6--7.9              1,541                20.7      34.9%±1.2%   12.1%±0.9%   8.3%±0.8%
   8--9.9              633                  8.5       29.0%±1.9%   10.6%±1.3%   7.4%±1.1%
   ≥10                 326                  4.4       27.9%±2.5%   7.3%±1.6%    4.1%±1.2%
  Involvement of LN                                                             
   No                  1,901                25.6      51.4%±1.2%   26.8%±1.1%   20.3%±1.0%
   Regional LN         4,820                65.0      37.8%±0.7%   14.4%±0.5%   9.5%±0.5%
   Distant LN          697                  9.4       31.2%±1.8%   8.1%±1.2%    4.7%±1.0%
  Extension of tumor                                                            
   No                  3,352                45.2      51.3%±0.9%   24.9%±0.8%   18.4%±0.7%
   Distant extension   4,066                54.8      32.0%±0.7%   10.7%±0.5%   6.7%±0.4%
  Race                                                                          
   White               6,113                82.4      40.7%±0.6%   17.1%±0.5%   12.2%±0.5%
   Black               924                  12.5      39.5%±1.6%   16.9%±1.3%   10.9%±1.1%
   Asian               375                  5.1       42.7%±2.6%   17.4%±2.1%   10.4%±1.7%

**Abbreviations:** OS, overall survival; SQCC, squamous cell carcinoma; AC, adenocarcinoma; LCC, large cell carcinoma; SMCC, small cell carcinoma; RT, radiotherapy; LN, lymph node.

###### 

Univariable analysis and Cox proportional hazards regression analysis

  Variable             Univariable analysis   Multivariable analysis                                    
  -------------------- ---------------------- ------------------------ --------- ------- -------------- ---------
  Age (years)                                                                                           
   0--39               Ref                                                       Ref                    
   40--49              1.859                  1.399--2.469             \<0.001   1.495   1.124--1.989   0.006
   50--59              1.960                  1.492--2.573             \<0.001   1.565   1.190--2.059   0.001
   60--69              2.171                  1.657--2.845             \<0.001   1.650   1.257--2.167   \<0.001
   70--79              2.714                  2.069--3.559             \<0.001   1.896   1.442--2.492   \<0.001
   80+                 3.348                  2.531--4.429             \<0.001   2.057   1.550--2.728   \<0.001
  Gender                                                                                                
   Male                Ref                                                       Ref                    
   Female              0.953                  0.907--1.001             0.054     0.893   0.849--0.939   \<0.001
  Pathologic grade                                                                                      
   Grade I             Ref                                                       Ref                    
   Grade II            1.350                  1.169--1.559             \<0.001   1.233   1.065--1.427   0.005
   Grade III           1.675                  1.457--1.927             \<0.001   1.394   1.210--1.606   \<0.001
   Grade IV            1.736                  1.504--2.004             \<0.001   1.389   1.718--1.637   \<0.001
  Histologic type                                                                                       
   SQCC                Ref                                                       Ref                    
   AC                  1.187                  1.114--1.265             \<0.001   1.083   1.014--1.156   0.017
   LCC                 1.341                  1.202--1.497             \<0.001   1.034   0.915--1.167   0.594
   SMCC                1.188                  1.117--1.263             \<0.001   0.955   0.863--1.057   0.375
   Others              0.866                  0.770--0.975             0.017     1.000   0.884--1.131   0.997
  Chemotherapy                                                                                          
   No                  Ref                                                       Ref                    
   Yes                 0.812                  0.773--0.854             \<0.001   0.561   0.530--0.593   \<0.001
  Radiotherapy                                                                                          
   No                  Ref                                                                              
   Yes                 1.010                  0.960--1.063             0.694                            
  Surgery                                                                                               
   No                  Ref                                                       Ref                    
   Yes                 0.387                  0.360--0.415             \<0.001   0.352   0.324--0.382   \<0.001
  Size (cm)                                                                                             
   \<2                 Ref                                                       Ref                    
   2--3.9              1.253                  1.100--1.427             0.001     1.107   0.971--1.621   0.127
   4--5.9              1.558                  1.373--1.769             \<0.001   1.259   1.107--1.432   \<0.001
   6--7.9              1.764                  1.547--2.012             \<0.001   1.357   1.187--1.552   \<0.001
   8--9.9              1.992                  1.722--2.305             \<0.001   1.422   1.225--1.651   \<0.001
   ≥10                 2.195                  1.860--2.590             \<0.001   1.509   1.274--1.788   \<0.001
  Involvement of LN                                                                                     
   No                  Ref                                                       Ref                    
   Regional LN         1.410                  1.330--1.494             \<0.001   1.279   1.204--1.658   \<0.001
   Distant LN          1.739                  1.583--1.911             \<0.001   1.456   1.321--1.604   \<0.001
  Extension of tumor                                                                                    
   No                  Ref                                                       Ref                    
   Distant extension   1.582                  1.505--1.662             \<0.001   1.333   1.265--1.406   \<0.001

**Abbreviations:** SQCC, squamous cell carcinoma; AC, adenocarcinoma; LCC, large cell carcinoma; SMCC, small cell carcinoma; LN, lymph node.

[^1]: These authors contributed equally to this work
